Tech Company Financing Transactions
Augustine Therapeutics Funding Round
Asabys Partners, AdBio Partners and Eli Lilly and Company participated in a $18 million Series A funding round for Augustine Therapeutics. The financing closed on 6/26/2024.
Transaction Overview
Company Name
Announced On
6/26/2024
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance the development of its lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Gaston Geenslaan 1
Leuven, 3001
Belgium
Leuven, 3001
Belgium
Phone
Undisclosed
Website
Email Address
Overview
Augustine Therapeutics was founded in 2019 as a spin-off of VIB and KU Leuven. Based on the groundbreaking neurological research of Prof. Ludo Van Den Bosch, this early drug discovery company is building a portfolio of first-in-class therapies for rare neuromuscular neurodegenerative diseases. Augustine Therapeutics' approach is based on new insights into the neuroprotective potential of small-molecule HDAC6 inhibitors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Gerhard Koenig
Chief Executive Officer
Sylvain Celanire
Chief Financial Officer
Christophe Van Vaeck
Vice President
Frederik Rombouts
Browse more venture capital transactions:
Prev: 6/26/2024: Otamiser venture capital transaction
Next: 6/26/2024: A24 Films venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs